On September 1, 2026, FDA posted five warning letters to peptide sellers. All five letters were dated August 24. All five followed website reviews conducted in July 2026.

Five companies. Five letters. One coordinated sweep.

The common thread in every letter: the "research use only" disclaimer did not protect them.

Here's what FDA looked at, what it found, and what it means.

The Five Companies

FDA posted warning letters to the following companies:

Peptide Partners LLC — Warning letter 735063, dated August 24, 2026
TXP Innovations LLC (dba Tex Peptides) — Warning letter 735067, dated August 24, 2026
Royal Peptides LLC — Warning letter 734884, dated August 24, 2026
NuScience Peptides LLC — Warning letter 733652, dated August 24, 2026
Peak Performance Peptides — Warning letter 735127, dated August 24, 2026

All letters are publicly available at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/.

What Products Were Cited

Across the five letters, FDA cited the following products as unapproved new drugs:

Semaglutide and tirzepatide
Retatrutide
SS-31 (elamipretide)
Tesamorelin, a tesamorelin/ipamorelin blend, and "Bimorelin"
PT-141 (bremelanotide)
Survodutide and mazdutide (one letter)
Bacteriostatic water sold for peptide reconstitution

The inclusion of bacteriostatic water is notable. Selling it alongside injectable peptides and reconstitution guides was treated as part of the evidence of intended human use.

Why "Research Use Only" Failed as a Defense

This is the most important thing in these letters for anyone in the peptide space.

FDA did not look at the disclaimer on the label. FDA looked at the totality of each website — and used that totality as evidence that the products were actually intended for human use, regardless of what the label said.

Specifically, FDA cited as evidence:

Weight loss, metabolic, and disease-related claims. If a website describes a compound's effects on obesity, metabolic function, sexual performance, or any other human health condition — FDA reads that as a human benefit claim, not a research description.

Bacteriostatic water sold alongside injectables. Bacteriostatic water has no laboratory research application. Its only use is for reconstituting compounds intended for injection. Selling it alongside peptides and reconstitution instructions signals the intended use.

Peptide calculators and guides. Two of the five letters cite the seller's "peptide calculator" — and one a "peptide guide" — as resources that, alongside bacteriostatic water, "provide the means to prepare an injectable drug for human administration." Those are FDA's words. A calculator is not a laboratory instrument; FDA read it as a patient-facing dosing tool.

The reconstitution pairing. Every letter names bacteriostatic water sold "as a solvent for reconstituting your products." One letter states it directly: selling the two together "demonstrates that you intend for your 'Bac water' to be used in combination for injection."

The combination of all of the above. Even if each element individually might have an innocent explanation, FDA evaluated the full context of each website — and concluded that the totality demonstrated products were marketed for human use.

The disclaimer at the bottom of the page carried no weight against that totality.

What FDA Can Do Now

Each company must respond to their warning letter within 15 business days of receipt. FDA has not published the precise receipt dates.

If FDA determines that responses are inadequate — or if companies fail to come into compliance — the agency can pursue:

Seizure of products
Injunction to halt operations
Criminal prosecution in serious cases

Warning letters are the beginning of an enforcement process, not the end. They also create a public record of violations that can be used in subsequent proceedings.

What This Does and Doesn't Change

What changed: FDA demonstrated, through five simultaneous letters from a single coordinated sweep, that the direct-to-consumer research-peptide model has a documented regulatory vulnerability. If your website contains human benefit claims, dosing tools, reconstitution guides, or injectable accessories — the "RUO" disclaimer does not provide legal protection.

What didn't change: These are warning letters — enforcement actions, not rule changes. They are not a PCAC decision. They are not a 503A or 503B list change. The legal status of the July advisory committee recommendations is completely unaffected by these letters.

The PCAC advisory vote recommended six peptides for the 503A bulks list. FDA must still complete formal rulemaking before any of those compounds can be lawfully compounded. That process is independent of this enforcement action.

The Two Different Models

These warning letters make the distinction between two fundamentally different access models clearer than any regulatory document has before.

The model FDA warned: A website operating under a "research use only" disclaimer, selling injectable compounds alongside reconstitution water, peptide calculators and guides, and human benefit claims to direct consumers.

The model the PCAC pathway would create: A licensed compounding pharmacy dispensing a compound under physician prescription, under state pharmacy board oversight, using established quality and safety standards — to a patient with a documented clinical indication.

These are not the same thing. They have never been the same thing. FDA's enforcement action documents what happens to the first model. The PCAC pathway, if completed through rulemaking, would be the second model — an entirely different regulatory framework.

Understanding that distinction matters for anyone trying to navigate this space accurately.

What to Watch

The closely coordinated timing — five letters, all dated the same day, all from the same July sweep — strongly suggests this was a planned enforcement initiative rather than five independent inspections.

Whether additional letters follow in subsequent weeks will signal whether this is an ongoing campaign or a targeted action against these specific companies.

The precedent these letters establish — that the totality of website content, not just the label, determines whether a compound is an unapproved new drug — will shape how FDA evaluates similar businesses going forward.

We'll cover every development as it happens.

→ Follow the latest at PeptidesGPT.com/research

Sources:

FDA Warning Letter: Peptide Partners LLC, 735063-08242026 — fda.gov
FDA Warning Letter: TXP Innovations LLC dba Tex Peptides, 735067-08242026 — fda.gov
FDA Warning Letter: Royal Peptides LLC, 734884-08242026 — fda.gov
FDA Warning Letter: NuScience Peptides LLC, 733652-08242026 — fda.gov
FDA Warning Letter: Peak Performance Peptides, 735127-08242026 — fda.gov
FDA PCAC Meeting July 23-24, 2026 — advisory-committee-calendar

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical or legal advice. Always consult a licensed healthcare provider before making decisions about your health or protocol.